← All Oruka Therapeutics, INC filings

Oruka Therapeutics, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
ORKA
Oruka Therapeutics, INC
DEF: Oruka Therapeutics 2026 Annual Meeting Proxy Statement
Oruka Therapeutics schedules its 2026 Annual Meeting of Stockholders for June 2, 2026, to address director elections, auditor ratification, and executive compensation.
NASDAQ
ORKA
Oruka Therapeutics, INC
DEFA14A: Oruka Therapeutics Sets Date for 2025 Annual Meeting, Outlines Voting Matters
Oruka Therapeutics, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on June 2, 2025, with key voting items including the election of directors, ratification of the accounting firm, and executive compensation.
NASDAQ
ORKA
Oruka Therapeutics, INC
DEF: Oruka Therapeutics Announces Annual Stockholders Meeting and Director Nominations
Oruka Therapeutics will hold its annual stockholders meeting virtually on June 2, 2025, to vote on director elections, auditor ratification, executive compensation, and the frequency of future compensation votes.
NASDAQ
ORKA
Oruka Therapeutics, INC
DEF 14A: Oruka Therapeutics Seeks Stockholder Approval for Series A Preferred Stock Conversion at Special Meeting
Oruka Therapeutics is holding a special meeting on November 14, 2024, to seek stockholder approval for the conversion of its Series A Non-Voting Convertible Preferred Stock into common stock, as required by Nasdaq listing rules.